Lantheus Completes Acquisition of Evergreen Theragnostics
Deal News | Apr 01, 2025 | Globenewswire
Lantheus Holdings, a leading company in radiopharmaceutical solutions, has successfully completed its acquisition of Evergreen Theragnostics. Announced in January, this strategic move aims to enhance Lantheus' capabilities across the radiopharmaceutical value chain by integrating Evergreen's manufacturing infrastructure and promising cancer-focused pipeline. The acquisition includes OCTEVY, a PET diagnostic agent targeting neuroendocrine tumors, complementing Lantheus' existing therapeutic candidate PNT2003, and advancing their clinical and pre-clinical theranostic offerings. CEO Brian Markison highlights the acquisition as a significant milestone that strengthens Lantheus' position in the market, enabling the company to better serve the complex demands of patients worldwide. Both companies have a strong presence in Massachusetts and New Jersey, with Lantheus' established history of over 65 years in the field.
Sectors
- Radiopharmaceuticals
- Healthcare
Geography
- United States – Both Lantheus and Evergreen Theragnostics are headquartered in the United States, thus making this geography relevant to the acquisition.
- Massachusetts – Lantheus is headquartered in Massachusetts, highlighting its primary operations location.
- New Jersey – Evergreen Theragnostics is based in New Jersey, marking it a key location for the developments discussed in the acquisition.
Industry
- Radiopharmaceuticals – This industry is relevant as both Lantheus and Evergreen Theragnostics operate within the radiopharmaceutical sector, focusing on the development, manufacturing, and commercialization of diagnostic and therapeutic agents.
- Healthcare – The healthcare industry is pertinent here due to the focus on improving patient outcomes through advanced radiopharmaceutical solutions for disease management.
Financials
- Not disclosed – The financial terms of the acquisition between Lantheus and Evergreen Theragnostics were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Lantheus Holdings, Inc. | Acquirer | Company | A leading company in the radiopharmaceutical sector focused on enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. |
| Evergreen Theragnostics, Inc. | Target | Company | A clinical-stage radiopharmaceutical company engaged in drug discovery and manufacturing services, headquartered in New Jersey. |
| Brian Markison | CEO of Lantheus | Person | Chief Executive Officer of Lantheus, providing leadership during the acquisition process. |